Table 2. HT-1080-R and ASPS-KY cells were treated for 72 hours with serial dilutions of the indicated SINE compounds with/without proteasome inhibitors at concentrations below their IC50.
| HT-1080-R | ||
|---|---|---|
| Compound | IC50 (μM) | Fold Change |
| KPT-185 | 4.3 | 1 |
| Bortezomib | 0.0048 | |
| KPT-185 + 4.1 nM Bortezomib | 0.11 | 39 |
| Carfilzomib | 0.0076 | |
| KPT-185 + 4.1 nM Carfilzomib | 0.28 | 15.4 |
| ASPS-KY | ||
| Compound | IC50 (μM) | Fold Change |
| Selinexor | 22 | 1 |
| Bortezomib | >>1 | |
| Selinexor + 1μM Bortezomib | 1.89 | 11.64 |
Proteasome inhibitors sensitized HT-1080-R and ASPS-KY cells to SINE compounds by 39- and 12-fold respectively.